Mesoblast (ADR) (MESO)
Develops FDA-approved Ryoncil for pediatric steroid-refractory acute graft-versus-host disease.
$15.35
vs last close−0.57 (−3.58%)
Something off on this page? Send us feedback.
EPSReportedEstimate
Oct '24Feb '25Apr '25Jul '25Aug '25Feb '26Apr '26Aug '26
Reported−$0.28−$0.42−$0.21−$0.43−$0.32−$0.31−$0.07−$0.13
Estimate−$0.31−$0.25−$0.35−$0.37−$0.20−$0.24−$0.08−$0.11
Surprise+9.7%−68.0%+38.3%−15.2%−60.0%−31.2%+11.7%−23.2%
RevenueReportedEstimate
Oct '24Feb '25Apr '25Jul '25Aug '25Feb '26Apr '26Aug '26
Reported$1.6M$3.2M$7.0M$14.0M$15.6M$51.3M$34.5M$69.0M
Estimate$3.5M$3.0M$7.5M$14.1M$14.1M$53.1M$29.2M$53.9M
Surprise−54.5%+7.3%−6.2%−0.8%+10.2%−3.2%+18.0%+28.0%
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2031 | $0.21 | — | — |
| Jun 2031 | $0.25 | — | — |
| Mar 2031 | $0.16 | — | — |
| Dec 2030 | −$0.10 | — | — |
| Sep 2030 | −$0.07 | — | — |
| Jun 2030 | −$0.15 | — | — |
| Mar 2030 | −$0.11 | — | — |
| Dec 2029 | −$0.24 | — | — |
| Sep 2029 | −$0.37 | — | — |
| Jun 2029 | −$0.49 | — | — |
| Mar 2029 | −$0.35 | — | — |
| Dec 2028 | −$0.43 | — | — |
| Sep 2028 | −$0.28 | — | — |
| Jun 2028 | −$0.31 | — | — |
| Mar 2028 | −$0.27 | — | — |
| Dec 2027 | −$0.31 | — | — |
| Sep 2027 | −$0.19 | — | — |
| Jun 2027 | −$0.26 | — | — |
| Mar 2027 | −$0.39 | — | — |
| Mar 2027 | −$0.15 | — | — |
| Sep 2026 | −$0.18 | — | — |
| Aug 2026 | −$0.11 | −$0.13 | −23.2% |
| Apr 2026 | −$0.08 | −$0.07 | +11.7% |
| Feb 2026 | −$0.24 | −$0.31 | −31.2% |
| Aug 2025 | −$0.20 | −$0.32 | −60.0% |
| Jul 2025 | |||
| Apr 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Dec 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Dec 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| Apr 2016 | |||
| Feb 2016 | |||
| Dec 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Sep 2031 | $0.21 | — | — | $184.8M | — | — | — |
| Jun 2031 | $0.25 | — | — | $176.7M | — | — | — |
| Mar 2031 | $0.16 | — | — | $144.8M | — | — | — |
| Dec 2030 | −$0.10 | — | — | $103.2M | — | — | — |
| Sep 2030 | −$0.07 | — | — | $105.5M | — | — | — |
| Jun 2030 | −$0.15 | — | — | $87.9M | — | — | — |
| Mar 2030 | −$0.11 | — | — | $74.0M | — | — | — |
| Dec 2029 | −$0.24 | — | — | $53.1M | — | — | — |
| Sep 2029 | −$0.37 | — | — | $14.1M | — | — | — |
| Jun 2029 | −$0.49 | — | — | $3.0M | — | — | — |
| Mar 2029 | −$0.35 | — | — | $4.1M | — | — | — |
| Dec 2028 | −$0.43 | — | — | $3.9M | — | — | — |
| Sep 2028 | −$0.28 | — | — | $2.4M | — | — | — |
| Jun 2028 | −$0.31 | — | — | $2.1M | — | — | — |
| Mar 2028 | −$0.27 | — | — | $2.1M | — | — | — |
| Dec 2027 | −$0.31 | — | — | $3.5M | — | — | — |
| Sep 2027 | −$0.19 | — | — | $7.6M | — | — | — |
| Jun 2027 | −$0.26 | — | — | $2.1M | — | — | — |
| Mar 2027 | −$0.39 | — | — | $3.5M | — | — | — |
| Mar 4, 2027 | −$0.15 | — | — | $87.9M | — | — | — |
| Sep 2026 | −$0.18 | — | — | $17.7M | — | — | — |
| Aug 26, 2026 | −$0.11 | −$0.13 | −23.2% | $53.9M | $69.0M | +28.0% | +8.0% |
| Apr 30, 2026 | −$0.08 | −$0.07 | +11.7% | $29.2M | $34.5M | +18.0% | +0.5% |
| Feb 26, 2026 | −$0.24 | −$0.31 | −31.2% | $53.1M | $51.3M | −3.2% | −6.3% |
| Aug 28, 2025 | −$0.20 | −$0.32 | −60.0% | $14.1M | $15.6M | +10.2% | −1.1% |
| Jul 29, 2025 | |||||||
| Apr 30, 2025 | |||||||
| Feb 26, 2025 | |||||||
| Oct 30, 2024 | |||||||
| Aug 28, 2024 | |||||||
| May 30, 2024 | |||||||
| Feb 28, 2024 | |||||||
| Dec 12, 2023 | |||||||
| Aug 30, 2023 | |||||||
| May 25, 2023 | |||||||
| Feb 27, 2023 | |||||||
| Nov 22, 2022 | |||||||
| Aug 30, 2022 | |||||||
| May 31, 2022 | |||||||
| Feb 24, 2022 | |||||||
| Nov 23, 2021 | |||||||
| Aug 31, 2021 | |||||||
| Jun 2, 2021 | |||||||
| Mar 2, 2021 | |||||||
| Nov 19, 2020 | |||||||
| Aug 26, 2020 | |||||||
| May 27, 2020 | |||||||
| Feb 26, 2020 | |||||||
| Dec 16, 2019 | |||||||
| Aug 29, 2019 | |||||||
| May 30, 2019 | |||||||
| Feb 20, 2019 | |||||||
| Nov 15, 2018 | |||||||
| Aug 29, 2018 | |||||||
| May 31, 2018 | |||||||
| Feb 27, 2018 | |||||||
| Nov 14, 2017 | |||||||
| Aug 29, 2017 | |||||||
| May 24, 2017 | |||||||
| Feb 26, 2017 | |||||||
| Nov 14, 2016 | |||||||
| Aug 25, 2016 | |||||||
| Apr 28, 2016 | |||||||
| Feb 16, 2016 | |||||||
| Dec 16, 2015 | |||||||
| Aug 17, 2015 |